The first gene-editing therapies for HIV/Aids are entering trials but the virus is proving once again that it is a master at ...

Lenacapavir is an injectable medicine that only needs to be taken twice a year, making it easier to use than daily HIV pills.

The Department of Health said the decision reflects its mandate to ensure that all citizens have access to safe, effective, ...

You can now be vaccinated against HIV – but that does not mean you can be reckless, warns the Department of Health ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead’s twice-yearly ...

The search for long-COVID treatments echoes the previous struggles against HIV/AIDS. Now researchers are taking lessons from ...

Women are disproportionately affected by HIV, making up nearly half of new infections globally and in India. Stigma, gender ...

Researchers in the TB Alliance informed the Union Conference on Lung Health in Copenhagen that Sorbequiline, a new antibiotic ...

In 2017, the Food and Drug Administration approved June’s Chimeric Antigen Receptor T (CAR-T) cell therapy for treating ...

Tatenda Makoni is a Zimbabwean-born medical student at the Medical College of Wisconsin whose work bridges global health and ...

Private sector leaders, philanthropists, and global health experts convened today at the B20 Global Health Breakout, held on the margins of the G20 Leaders' Summit, to spotlight a new wave of ...

Merck , known as MSD outside of the United States and Canada, today announced topline results from the pivotal double-blind Phase 3 trial of the investigational, once-daily, oral, two-drug, ...